Cannabinoids Biology: The Search for New Therapeutic Targets

by: Christian C Felder, Amy K Dickason-Chesterfield, Steven A Moore

Mol. Interv., Vol. 6, No. 3. (1 June 2006), pp. 149-161.

View FullText article

DOI, HighWire, Pubmed, Hubmed

Reviews [Write a review of this article]

There are no reviews of this article

Find related articles from these CiteULike users

xico, WetBiology (group)

Find related articles with these CiteULike tags

2-ag, anandamide, cannabinoid, review, signalling, target, therapy

Abstract

Cannabinoids, in the form of marijuana plant extracts, have been used for thousands of years for a wide variety of medical conditions, ranging from general malaise and mood disorders to more specific ailments, such as pain, nausea, and muscle spasms. The discovery of tetrahydrocannabinol, the active principal in marijuana, and the identification and cloning of two cannabinoid receptors (i.e., CB1 and CB2) has subsequently led to biomedical appreciation for a family of endocannabinoid lipid transmitters. The biosynthesis and catabolism of the endocannabinoids and growing knowledge of their broad physiological roles are providing insight into potentially novel therapeutic targets. Compounds directed at one or more of these targets may allow for cannabinoid-based therapeutics with limited side effects and abuse liability. 10.1124/mi.6.3.6

@article{citeulike:1601663, abstract = {Cannabinoids, in the form of marijuana plant extracts, have been used for thousands of years for a wide variety of medical conditions, ranging from general malaise and mood disorders to more specific ailments, such as pain, nausea, and muscle spasms. The discovery of tetrahydrocannabinol, the active principal in marijuana, and the identification and cloning of two cannabinoid receptors (i.e., CB1 and CB2) has subsequently led to biomedical appreciation for a family of endocannabinoid lipid transmitters. The biosynthesis and catabolism of the endocannabinoids and growing knowledge of their broad physiological roles are providing insight into potentially novel therapeutic targets. Compounds directed at one or more of these targets may allow for cannabinoid-based therapeutics with limited side effects and abuse liability. 10.1124/mi.6.3.6}, author = {Felder, Christian C. and Dickason-Chesterfield, Amy K. and Moore, Steven A. }, citeulike-article-id = {1601663}, doi = {10.1124/mi.6.3.6}, journal = {Mol. Interv.}, keywords = {2-ag, anandamide, cannabinoid, review, signalling, target, therapy}, month = {June}, number = {3}, pages = {149--161}, posted-at = {2007-08-28 20:03:46}, priority = {2}, title = {Cannabinoids Biology: The Search for New Therapeutic Targets}, url = {http://dx.doi.org/10.1124/mi.6.3.6}, volume = {6}, year = {2006} }

RIS record

TY - JOUR ID - citeulike:1601663 L3 - citeulike-article-id:1601663 TI - Cannabinoids Biology: The Search for New Therapeutic Targets JF - Mol. Interv. VL - 6 IS - 3 SP - 149 EP - 161 N2 - Cannabinoids, in the form of marijuana plant extracts, have been used for thousands of years for a wide variety of medical conditions, ranging from general malaise and mood disorders to more specific ailments, such as pain, nausea, and muscle spasms. The discovery of tetrahydrocannabinol, the active principal in marijuana, and the identification and cloning of two cannabinoid receptors (i.e., CB1 and CB2) has subsequently led to biomedical appreciation for a family of endocannabinoid lipid transmitters. The biosynthesis and catabolism of the endocannabinoids and growing knowledge of their broad physiological roles are providing insight into potentially novel therapeutic targets. Compounds directed at one or more of these targets may allow for cannabinoid-based therapeutics with limited side effects and abuse liability. 10.1124/mi.6.3.6 KW - 2-ag KW - anandamide KW - cannabinoid KW - review KW - signalling KW - target KW - therapy AU - Felder, Christian AU - Dickason-Chesterfield, Amy AU - Moore, Steven PY - 2006/06/01/ UR - http://dx.doi.org/10.1124/mi.6.3.6 ER -

RIS BibTeX